$179.10
4.052.31%
At close: -
$179.93
0.830.46%
After Hours: 7:17 PM EDT
Comments
Loading...
AbbVie Analyst Ratings and Price Targets | NYSE:ABBV | Benzinga
AbbVie Inc has a consensus price target of $197.93 based on the ratings of 33 analysts. The high is $241 issued by Morgan Stanley on April 9, 2025. The low is $133 issued by CFRA on February 9, 2023. The 3 most-recent analyst ratings were released by Morgan Stanley, Goldman Sachs, and Wells Fargo on April 9, 2025, April 8, 2025, and March 5, 2025, respectively. With an average price target of $225 between Morgan Stanley, Goldman Sachs, and Wells Fargo, there's an implied 25.05% upside for AbbVie Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Goldman Sachs
Wells Fargo
B of A Securities
Citigroup
1calculated from analyst ratings
Analyst Ratings for AbbVie
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 33.94% | Morgan Stanley | Terence Flynn66% | $239 → $241 | Maintains | Overweight | Get Alert |
| 04/08/2025 | Buy Now | 7.82% | Goldman Sachs | Asad Haider 38% | → $194 | Assumes | → Neutral | Get Alert |
| 03/05/2025 | Buy Now | 33.39% | Wells Fargo | Mohit Bansal69% | $210 → $240 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | 23.94% | B of A Securities | Tim Anderson53% | $200 → $223 | Maintains | Neutral | Get Alert |
| 02/03/2025 | Buy Now | 19.49% | Citigroup | Geoff Meacham60% | $205 → $215 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 20.6% | Truist Securities | Srikripa Devarakonda38% | $211 → $217 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 5.6% | UBS | Navin Jacob67% | $181 → $190 | Maintains | Neutral | Get Alert |
| 02/03/2025 | Buy Now | 16.71% | Wells Fargo | Mohit Bansal69% | $195 → $210 | Maintains | Overweight | Get Alert |
| 02/03/2025 | Buy Now | 32.83% | Morgan Stanley | Terence Flynn66% | $224 → $239 | Maintains | Overweight | Get Alert |
| 02/03/2025 | Buy Now | 22.27% | Raymond James | Gary Nachman56% | $218 → $220 | Reiterates | Outperform → Outperform | Get Alert |
| 02/03/2025 | Buy Now | 18.94% | Guggenheim | Vamil Divan72% | $212 → $214 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 19.49% | BMO Capital | Evan David Seigerman44% | $208 → $215 | Maintains | Outperform | Get Alert |
| 01/28/2025 | Buy Now | 13.93% | Citigroup | Geoff Meacham60% | $215 → $205 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 17.27% | Truist Securities | Srikripa Devarakonda38% | $215 → $211 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 22.27% | Piper Sandler | Christopher Raymond54% | $212 → $220 | Maintains | Overweight | Get Alert |
| 12/10/2024 | Buy Now | 6.15% | B of A Securities | Tim Anderson53% | → $191 | Reinstates | → Neutral | Get Alert |
| 11/22/2024 | Buy Now | 14.49% | Leerink Partners | David Risinger72% | → $206 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/15/2024 | Buy Now | 13.93% | Wolfe Research | Alexandria Hammond37% | → $205 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | 11.15% | JP Morgan | Chris Schott59% | $210 → $200 | Maintains | Overweight | Get Alert |
| 11/12/2024 | Buy Now | 19.49% | Citigroup | Geoff Meacham60% | $226 → $215 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 15.6% | BMO Capital | Evan David Seigerman44% | $228 → $208 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 24.49% | Morgan Stanley | Terence Flynn66% | $231 → $224 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 22.83% | Guggenheim | Vamil Divan72% | $212 → $221 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | — | Argus Research | David Toung71% | — | Upgrade | Hold → Buy | Get Alert |
| 10/31/2024 | Buy Now | 26.72% | BMO Capital | Evan David Seigerman44% | $220 → $228 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 25.6% | Citigroup | Geoff Meacham60% | $215 → $226 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 11.15% | UBS | Navin Jacob67% | $195 → $200 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 28.38% | Morgan Stanley | Terence Flynn66% | $218 → $231 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 19.49% | Citigroup | Andrew Baum70% | $170 → $215 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 8.38% | B of A Securities | Geoff Meacham60% | $185 → $195 | Maintains | Neutral | Get Alert |
| 10/17/2024 | Buy Now | 22.27% | BMO Capital | Evan David Seigerman44% | $214 → $220 | Maintains | Outperform | Get Alert |
| 10/17/2024 | Buy Now | 12.82% | Bernstein | Aaron Gal55% | → $203 | Initiates | → Market Perform | Get Alert |
| 10/10/2024 | Buy Now | 19.49% | Truist Securities | Srikripa Devarakonda38% | $210 → $215 | Maintains | Buy | Get Alert |
| 10/09/2024 | Buy Now | 8.38% | UBS | Navin Jacob67% | $185 → $195 | Maintains | Neutral | Get Alert |
| 10/07/2024 | Buy Now | 17.82% | Barclays | Carter Gould56% | $200 → $212 | Maintains | Overweight | Get Alert |
| 10/07/2024 | Buy Now | 25.05% | TD Cowen | Steve Scala68% | $195 → $225 | Maintains | Buy | Get Alert |
| 08/23/2024 | Buy Now | 16.16% | Piper Sandler | Christopher Raymond54% | $196 → $209 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 21.16% | Morgan Stanley | Terence Flynn66% | $211 → $218 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 11.15% | Cantor Fitzgerald | Louise Chen51% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/26/2024 | Buy Now | 2.82% | UBS | Navin Jacob67% | $172 → $185 | Maintains | Neutral | Get Alert |
| 07/26/2024 | Buy Now | 11.15% | Cantor Fitzgerald | Louise Chen51% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/26/2024 | Buy Now | 16.71% | Truist Securities | Robyn Karnauskas55% | $195 → $210 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2024 | Buy Now | 13.93% | Wells Fargo | Mohit Bansal69% | $200 → $205 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | 11.15% | Barclays | Carter Gould56% | $187 → $200 | Maintains | Overweight | Get Alert |
| 07/25/2024 | Buy Now | 16.71% | JP Morgan | Chris Schott59% | $190 → $210 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | 18.94% | BMO Capital | Evan David Seigerman44% | $180 → $214 | Maintains | Outperform | Get Alert |
| 07/11/2024 | Buy Now | 8.93% | Morgan Stanley | Terence Flynn66% | $191 → $196 | Maintains | Overweight | Get Alert |
| 07/09/2024 | Buy Now | 11.15% | Cantor Fitzgerald | Louise Chen51% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/02/2024 | Buy Now | 5.6% | Piper Sandler | Christopher Raymond54% | $190 → $190 | Maintains | Overweight | Get Alert |
| 06/20/2024 | Buy Now | 11.15% | Cantor Fitzgerald | Louise Chen51% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 06/18/2024 | Buy Now | 5.6% | Piper Sandler | Christopher Raymond54% | $185 → $190 | Maintains | Overweight | Get Alert |
| 06/05/2024 | Buy Now | 2.82% | HSBC | Rajesh Kumar63% | → $185 | Upgrade | Hold → Buy | Get Alert |
| 05/17/2024 | Buy Now | 11.15% | Cantor Fitzgerald | Louise Chen51% | → $200 | Initiates | → Overweight | Get Alert |
| 04/29/2024 | Buy Now | 3.93% | Barclays | Carter Gould56% | $195 → $187 | Maintains | Overweight | Get Alert |
| 04/29/2024 | Buy Now | 0.04% | BMO Capital | Evan David Seigerman44% | $195 → $180 | Maintains | Outperform | Get Alert |
| 03/27/2024 | Buy Now | 8.38% | Barclays | Carter Gould56% | $185 → $195 | Maintains | Overweight | Get Alert |
| 03/22/2024 | Buy Now | 5.6% | Guggenheim | Vamil Divan72% | $188 → $190 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 5.04% | Raymond James | Gary Nachman56% | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | 8.38% | Truist Securities | Robyn Karnauskas55% | $180 → $195 | Maintains | Buy | Get Alert |
| 02/05/2024 | Buy Now | 11.15% | Wells Fargo | Mohit Bansal69% | $180 → $200 | Maintains | Overweight | Get Alert |
| 02/05/2024 | Buy Now | 5.04% | Raymond James | Gary Nachman56% | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 8.38% | BMO Capital | Evan David Seigerman44% | $187 → $195 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 2.82% | Barclays | Carter Gould56% | $175 → $185 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | — | William Blair | Tim Lugo32% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | -2.74% | Barclays | Carter Gould56% | $170 → $175 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | 0.04% | Wells Fargo | Mohit Bansal69% | $195 → $180 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | -13.3% | HSBC | Rajesh Kumar63% | $167 → $156 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2023 | Buy Now | -3.85% | Goldman Sachs | Chris Shibutani54% | → $173 | Upgrade | Neutral → Buy | Get Alert |
| 12/01/2023 | Buy Now | 0.59% | Raymond James | Gary Nachman56% | $177 → $181 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | -16.63% | Deutsche Bank | James Shin32% | → $150 | Initiates | → Hold | Get Alert |
| 10/30/2023 | Buy Now | 8.93% | Morgan Stanley | Terence Flynn66% | $193 → $196 | Maintains | Overweight | Get Alert |
| 10/30/2023 | Buy Now | -5.52% | Barclays | Carter Gould56% | $160 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/11/2023 | Buy Now | 7.26% | Morgan Stanley | Terence Flynn66% | $189 → $193 | Maintains | Overweight | Get Alert |
| 09/29/2023 | Buy Now | -1.63% | Raymond James | Gary Nachman56% | → $177 | Initiates | → Outperform | Get Alert |
| 07/28/2023 | Buy Now | -5.52% | Piper Sandler | Christopher Raymond54% | $163 → $170 | Maintains | Overweight | Get Alert |
| 07/25/2023 | Buy Now | — | William Blair | Tim Lugo32% | — | Initiates | → Market Perform | Get Alert |
| 07/14/2023 | Buy Now | -7.19% | HSBC | Rajesh Kumar63% | → $167 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | 1.15% | Morgan Stanley | Terence Flynn66% | $182 → $182 | Reiterates | Overweight → Overweight | Get Alert |
| 04/28/2023 | Buy Now | -4.96% | Guggenheim | Vamil Divan72% | $172 → $171 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | 1.15% | Morgan Stanley | Terence Flynn66% | $181 → $182 | Maintains | Overweight | Get Alert |
| 04/28/2023 | Buy Now | 8.38% | Wells Fargo | Mohit Bansal69% | $200 → $195 | Maintains | Overweight | Get Alert |
| 04/13/2023 | Buy Now | -11.08% | Barclays | Carter Gould56% | $155 → $160 | Maintains | Equal-Weight | Get Alert |
| 04/10/2023 | Buy Now | 0.59% | Morgan Stanley | Terence Flynn66% | $178 → $181 | Maintains | Overweight | Get Alert |
| 04/05/2023 | Buy Now | — | Argus Research | Jasper Hellweg69% | — | Downgrade | Buy → Hold | Get Alert |
| 03/01/2023 | Buy Now | -4.41% | Guggenheim | Vamil Divan72% | → $172 | Initiates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | — | Wolfe Research | Tim Anderson53% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 02/10/2023 | Buy Now | -15.52% | UBS | Navin Jacob67% | $150 → $152 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -14.97% | SVB Leerink | David Risinger72% | $135 → $153 | Upgrade | Underperform → Market Perform | Get Alert |
| 02/10/2023 | Buy Now | -14.41% | Atlantic Equities | Steve Chesney57% | $157 → $154 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -1.07% | Morgan Stanley | Terence Flynn66% | $182 → $178 | Maintains | Overweight | Get Alert |
| 02/10/2023 | Buy Now | -9.41% | Piper Sandler | Christopher Raymond54% | $157 → $163 | Maintains | Overweight | Get Alert |
| 02/09/2023 | Buy Now | 0.04% | Truist Securities | Robyn Karnauskas55% | → $180 | Reiterates | → Buy | Get Alert |
| 02/09/2023 | Buy Now | -8.3% | Evercore ISI Group | Gavin Clark-Gartner37% | $159 → $165 | Maintains | Outperform | Get Alert |
| 02/09/2023 | Buy Now | -26.08% | CFRA | — | $151 → $133 | Downgrade | Hold → Sell | Get Alert |
| 02/06/2023 | Buy Now | -7.19% | BMO Capital | Gary Nachman56% | $169 → $167 | Maintains | Outperform | Get Alert |
| 01/31/2023 | Buy Now | -16.63% | UBS | Navin Jacob67% | $147 → $150 | Maintains | Neutral | Get Alert |
| 01/17/2023 | Buy Now | -12.74% | Piper Sandler | Christopher Raymond54% | $155 → $157 | Maintains | Overweight | Get Alert |
| 01/05/2023 | Buy Now | 0.04% | Truist Securities | Robyn Karnauskas55% | $160 → $180 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -14.41% | Evercore ISI Group | Gavin Clark-Gartner37% | $156 → $154 | Maintains | Outperform | Get Alert |
| 12/14/2022 | Buy Now | -8.3% | B of A Securities | Geoff Meacham60% | $162 → $165 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for AbbVie (ABBV) stock?
The latest price target for AbbVie (NYSE:ABBV) was reported by Morgan Stanley on April 9, 2025. The analyst firm set a price target for $241.00 expecting ABBV to rise to within 12 months (a possible 33.94% upside). 55 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbbVie (ABBV)?
The latest analyst rating for AbbVie (NYSE:ABBV) was provided by Morgan Stanley, and AbbVie maintained their overweight rating.
When was the last upgrade for AbbVie (ABBV)?
The last upgrade for AbbVie Inc happened on November 22, 2024 when Leerink Partners raised their price target to $206. Leerink Partners previously had a market perform for AbbVie Inc.
When was the last downgrade for AbbVie (ABBV)?
The last downgrade for AbbVie Inc happened on December 18, 2023 when HSBC changed their price target from $167 to $156 for AbbVie Inc.
When is the next analyst rating going to be posted or updated for AbbVie (ABBV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating AbbVie (ABBV) correct?
While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a maintained with a price target of $239.00 to $241.00. The current price AbbVie (ABBV) is trading at is $179.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.